initial public offerings (IPOs) trading on American exchanges

Sunday, September 29, 2024

IPOs this week : Sept 30 - Oct 4, 24 (wk 40)

IPOs expected to price

  • FrontView REIT (FVR) is expected to price its IPO and begin to trade next week. The Dallas-based company plans to raise $251 million and be valued at $508 million at the midpoint of its expected price range of $17 to $21. FrontView REIT is involved in acquiring, owning, and managing outparcel properties that are net leased to a diversified group of tenants. 
  • Aerospace engine aftermarket services company StandardAero (SARO). StandardAero has filed to raise $100 million in an IPO, although the final figure could be higher.
  • EV parts maker ZJK Industrial Co. (ZJK) is raising $6.3M by offering 1.3 million shares at a price range of $4.00 to $6.00.


Spinoffs 

  • Curbline will start trading on the New York Stock Exchange under the ticker symbol CURB on October 1 after spinning off from SITE Centers (NYSE:SITC). Curbline is expected to be capitalized with $600 million of cash at the time of the spin-off in addition to a $400 million unsecured line of credit, a $100 million unsecured draw term loan, and no indebtedness. Notably, Curbline will be the first public real estate company exclusively dedicated to convenience properties, which are described as retail sites or strip malls without a big-box or grocery store to anchor them. 
  • South Bow Corporation will begin trading as a standalone company after spinning off from TC Energy (TSX:TRP:CA). Shareholders will receive one new common share of TC Energy and 0.2 of a common share in South Bow Corporation in exchange for each common share of TC Energy held. After the business separation, TC Energy will continue to focus on natural gas pipeline infrastructure, power and energy business driven by nuclear and hydro energy storage, while South Bow will focus on the liquid pipeline business.

Friday, September 27, 2024

BioAge Labs (BIOA) began trading on the Nasdaq on Thr 26 Sept 24

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. 
  • Founded by Kristen Fortney and Eric Morgen on April 1, 2015 
  • Headquartered in Richmond, CA.
  • Website: bioagelabs.com
  • Employees: 59

Tuesday, September 17, 2024

Kairos Pharma (KAPA) began trading on the NYSE on Mon 16 Sept 24

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. 
  • Sector(s): Healthcare
  • Industry: Biotechnology
  • Formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016
  • Incorporated in 2013 
  • HQ in Los Angeles, California.
  • https://kairospharma.com
 Kairos Pharma (NYSEMKT:KAPA) priced on Monday its initial public offering of 1.5M shares of common stock at a public offering price of $4 per share. The gross proceeds from the offering are expected to be $6.2M.
 

Thursday, September 12, 2024

Fulcrum Therapeutics (FULC) : Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 

― Fulcrum to suspend future losmapimod development 

― Robust cash position enables Fulcrum to continue its mission to develop therapies addressing diseases of high unmet need including pociredir for the treatment of sickle cell disease (SCD)
 
 
 
 
 
 



Fulcrum Therapeutics is a biopharmaceutical company that focuses on developing small molecule therapies to treat rare diseases. The company was founded in Cambridge, Massachusetts in July 2016 by Third Rock Ventures.
It went public on July 17, 2019.

About the REACH Trial
REACH (NCT05397470) is a Phase 3 multi-center, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of losmapimod for the treatment of FSHD. The trial enrolled 260 patients who were randomized 1:1 to receive either losmapimod, administered orally as a 15 mg tablet twice a day, or placebo over a 48-week treatment period. The primary endpoint was the absolute change from baseline in Reachable Workspace (RWS). Secondary endpoint measurements included Muscle Fat Infiltration (MFI) as measured by MRI, shoulder abductor strength as measured by hand-held dynamometry, Patient Global Impression of Change (PGIC), and the Neuro QoL Upper Extremity.

About FSHD
FSHD is a serious, rare, progressive and debilitating disease for which there are no approved treatments. It is characterized by fat infiltration of skeletal muscle leading to muscular atrophy involving primarily the face, scapula and shoulders, upper arms, and abdomen. Impact on patients includes relentless and accumulating muscle and functional loss impacting their ability to perform activities of daily living, loss of upper limb function, loss of mobility and independence, and chronic pain. FSHD is one of the most common forms of muscular dystrophy and has an estimated patient population of 30,000 in the United States alone.

FTC Solar (FTCI) : 3-year performance

ticker:  FTCI


CN Energy Group (CNEY) : 3-year performance

CN Energy Group engages in the manufacture and supply of wood-based activated carbon primarily in China. The company's activated carbon is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production.
  • Sector(s): Basic Materials
  • Industry: Specialty Chemicals
  • Founded in November, 2018 
  • Headquartered in Lishui City, China
  • Full Time Employees: 30
  • https://www.cneny.com
ticker: CNEY



daily

Wednesday, September 11, 2024

PureCycle (PCT) : 3-year performance

PureCycle is a plastic recycling company that holds a global license to commercialize a solvent-based purification recycling technology. The technology was developed by Procter & Gamble and restores waste polypropylene into virgin-like resin

  • Sector(s): Industrials
  • Industry: Pollution & Treatment Controls
  • Full Time Employees: 146
  • founded in 2015 and is headquartered in Orlando, Florida
  • https://www.purecycle.com
PureCycle Technologies (PCT) went public and listed on the Nasdaq on March 18, 2021. 
Business combination with Roth CH Acquisition I Co. (NASDAQ: ROCH)



daily